ReviewCurrent cardiology reports2026
Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewPericarditis - the inflammation of the pericardial sac - has a generally benign course, although recurrences may occur in 15-30% of patients within 18 months, even after an initial uncomplicated course. For a long time, the scarcity of animal models has limited a deeper understanding of the pathophysiology of pericarditis. RECENT
findingsA number of stimuli, such as talc and bacterial products containing aluminum, were used in animal models to trigger the inflammation of the pericardial sac. Today, we know that such irritants represent canonical stimuli for the activation of the NACHT, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome, an intracellular macromolecular complex responsible for the production and secretion of active interleukin-1 β (IL-1β), a pro-inflammatory cytokine that promotes pericardial inflammation. This evidence supports the central role of the NLRP3 inflammasome/IL-1β axis in driving acute inflammation of the pericardium and subsequent flares, as indirectly highlighted in seminal clinical trials of anakinra (AIRTRIP trial), rilonacept (RHAPSODY trial), and goflikicept. More recently, cannabidiol (CBD, derived from Cannabis sativa) has been found to block the NLRP3 inflammasome activation in vitro and in vivo. Preliminary positive findings have been reported in patients with ongoing recurrent pericarditis in the MAvERIC-Pilot study, while the phase III MAVERIC-2 trial is exploring the impact of CBD among patients with a history of recurrent pericarditis in stable control scheduled to discontinue an IL-1 blocker. The activation of the NLRP3 inflammasome/IL-1β axis supports auto-inflammation as a central event driving recurrences, and its targeted therapeutic inhibition results as a game changer to reduce the risk of recurrences and improve patients' quality of life. Accordingly, a shift moving from the prescription of glucocorticoids as second-line therapy in favor of IL-1 blockers, particularly in those patients presenting with an auto-inflammatory phenotype, is ongoing. To this end, an imaging-guided approach may help choosing the best treatment and monitoring its effects across time, thus allowing a personalized approach to patients with recurrent pericarditis.
Indexed as
Identifiers
42189384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.